David Rudolph, DO
Internal Medicine · Newnan, GANPI 1881836013
Payments from drug & device makers
Across 295 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$587
- Johnson & Johnson$417
- Braintree Laboratories, Inc.$372
- Takeda Pharmaceuticals U.S.A., Inc.$219
- Ardelyx, Inc.$219
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,62092%
- Education$3918%
- Gifts$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 90 | $1,381 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 39 | $587 |
| Johnson & Johnson | 17 | $417 |
| Braintree Laboratories, Inc. | 36 | $372 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $219 |
| Ardelyx, Inc. | 11 | $219 |
| Pfizer | 11 | $191 |
| Sanofi | 6 | $175 |
| Regeneron Healthcare Solutions, Inc. | 5 | $156 |
| Intercept Pharmaceuticals, Inc. | 8 | $151 |
| Merck | 7 | $142 |
| Gilead | 7 | $142 |
| Phathom Pharmaceuticals, Inc. | 8 | $130 |
| Lilly USA, LLC | 4 | $85 |
| Madrigal Pharmaceuticals | 3 | $77 |
| Romark Laboratories, LC | 3 | $72 |
| Ipsen Biopharmaceuticals, Inc | 3 | $69 |
| QOL Medical, LLC | 3 | $66 |
| Ironwood Pharmaceuticals, Inc | 4 | $62 |
| Bristol Myers Squibb | 2 | $37 |
| Aimmune Therapeutics, Inc. | 2 | $31 |
| Mauna Kea Technologies, Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
| Ferring Pharmaceuticals Inc. | 2 | $27 |
| Axonics, Inc. | 1 | $26 |
| Biocon Biologics Inc | 1 | $22 |
| Orphalan Inc | 1 | $21 |
| Celltrion USA Inc. | 1 | $19 |
| Olympus America Inc. | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Shionogi Inc | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $13 |
How this compares
$5,047 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 24 | $90,848 |
| Humira(Cf) PenAdalimumab | 13 | $88,194 |
| CreonLipase/Protease/Amylase | 39 | $82,477 |
| LinzessLinaclotide | 23 | $23,624 |
| Mesalamine | 18 | $19,247 |
| MotegrityPrucalopride Succinate | 16 | $13,098 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 66 | $9,256 |
| Dexlansoprazole DrDexlansoprazole | 26 | $7,630 |
| Budesonide DrBudesonide | 37 | $6,976 |
| TrulancePlecanatide | 11 | $6,918 |
| Pantoprazole Sodium | 308 | $2,649 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 11 | $1,756 |
| Famotidine | 136 | $1,457 |
| Sucralfate | 26 | $1,367 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 19 | $1,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,381 | $106,10162 claims |
| Aimmune Therapeutics, Inc.Zenpep | $31 | $90,84824 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu, Trulance | $587 | $16,17477 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $219 | $13,09816 claims |
| Braintree Laboratories, Inc.Sutab | $372 | $1,75611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Newnan
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.